ISCO (International Stem Cell) PB Ratio: (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISCO International Stem Cell Corp ISCO
28 GF Score
Price $0.18
GF Value $0.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is International Stem Cell PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-18), International Stem Cell's share price is $0.18. International Stem Cell's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.53. Hence, International Stem Cell's PB Ratio of today is .

The historical rank and industry rank for International Stem Cell's PB Ratio or its related term are showing as below:

During the past 13 years, International Stem Cell's highest PB Ratio was 15.95. The lowest was 1.16. And the median was 4.35.

ISCO's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.82
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was 3.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 3.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of International Stem Cell was 129.20% per year. The lowest was -69.20% per year. And the median was 3.25% per year.

Back to Basics: PB Ratio


International Stem Cell  (OTCPK:ISCO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


International Stem Cell PB Ratio Related Terms


International Stem Cell PB Ratio Historical Data

* Premium members only.

The historical data trend for International Stem Cell's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell PB Ratio Chart

International Stem Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

International Stem Cell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ISCO vs ZVSA, AXIM, HEPA: PB Ratio Comparison

For the Biotechnology subindustry, International Stem Cell's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's PB Ratio distribution charts can be found below:

* The bar in red indicates where International Stem Cell's PB Ratio falls into.


ISCO
28GF Score
International Stem Cell Corp ISCO
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Stem Cell PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

International Stem Cell's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.18/-0.527
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.18 is trading 38.5% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • PB Ratio:
  • GF Value™: $0.13 vs. price of $0.18 (38.5% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
28GF Score

Get the complete analysis for ISCO

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.13
GF Value